ClinicalTrials.gg
Status unknownNCT04689100Updated Dec 30, 2020

Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

A Phase 1 interventional study of JMT101 and JMT101 in Advanced Solid Tumor, sponsored by Shanghai JMT-Bio Inc.. Status unknown at 9 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-12-30.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 years 8 months after the study started (first participant enrolled Apr 2017, registered Dec 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
259
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a Phase I, open label, multi-center study of to evaluate the safety and efficacy of JMT101 in patients with advanced solid tumor.

Read the detailed description

The objective of the trial is to evaluate the safety and efficacy of JMT101 in patients with advanced solid tumor.

This study consists of two parts (Stage I and Stage II). Stage I was a dose escalation study, and Stage II was a dose expansion study.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Shanghai JMT-Bio Inc. is the lead sponsor of 42 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Monotherapy: or cytologically confirmed, advanced solid tumor, harboring RAS wild type; Combined with chemotherapy: Pathologically or cytologically confirmed, locally advanced / colorectal cancer, harboring RAS and BRAF V600E wild type.
  • At least 1 according to 1.1;
  • score 0 or 1;
  • Stable for more than 14 days of or spinal cord compression.

Exclusion criteria

Exclusion Criteria:

  • Receipt of any EGFR inhibitors within 5 months prior to the first dose of study treatment.
  • The second primary malignant tumor was diagnosed within 5 years prior to the first dose of study treatment.
  • Known to any ingredient of JMT101 or their ;
  • Major surgery within prior 4 weeks of first treatment.
  • Receiving an product in another clinical study within 4 weeks;
  • History of serious systemic diseases;
  • Pregnancy or lactating wo
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
259 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Cohort

    Monotherapy: Six dose levels of JMT101 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design. Combined with chemotherapy: Three dose levels of JMT101 will be tested by a conventional 3 + 3 study design. The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days).

    Drug: JMT101

  • Experimental
    Dose Expansion Cohort

    Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.

    Drug: JMT101

Interventions

  • DrugJMT101

    Monotherapy: Accelerated titration method, IV infusion QW; Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles)

    Also known as: FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);

  • DrugJMT101

    IV infusion Q2W (28-day cycles)

    Also known as: FOLFIRI; mFOLFOX6; Irinotecan;

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (defined by the Common Terminology Criteria for Adverse Events version 4.03 (CTCAE V4.03)).

    Time frame: From enrollment until 30 days after the last dose

  2. Number of Subjects Experiencing DLTs (Dose Limiting Toxicity).

    Time frame: Time from the first dose of study drug up to 4 weeks

  3. Maximum Tolerated Dose (MTD)

    Time frame: 28 days

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: From first dose to disease progression or end of study, an average of 1 year

  2. Disease control rate (DCR).

    Time frame: From first dose to disease progression or end of study, an average of 1 year

  3. Progression free survival (PFS).

    Time frame: From first dose to disease progression or end of study, an average of 1 year

  4. Overall survival (OS).

    Time frame: From first dose to death or end of study, an average of 1 year

  5. Area under the concentration curve from time 0 to the concentration at last time point (AUC0-last) of JMT101.

    Time frame: From enrollment until 30 days after the last dose

  6. Maximum measured plasma concentration (Cmax) of JMT101.

    Time frame: From enrollment until 30 days after the last dose

  7. Time to maximum plasma concentration (Tmax) of JMT101.

    Time frame: From enrollment until 30 days after the last dose

  8. Half-life (T1/2) of JMT101.

    Time frame: From enrollment until 30 days after the last dose

  9. Immunogenicity profile of JMT101.

    Blood samples will be collected from subjects post treatment for assessment to detect the presence of anti-drug antibodies(ADA) and neutralizing antibodies by electrochemical luminescence(ECL).

    Time frame: From enrollment until 30 days after the last dose

  10. Potential biomarkers detected in plasma or tumor issue DNA.

    The content of RAS(reticular activating system), EGFR(epidermal growth factor receptor), BRAF(B-Raf proto-oncogene) gene will be detected.

    Time frame: From enrollment up to disease progression, an average of 1 year

07

Study locations

8 of 9 sites recruiting
  • Beijing Luhe Hospital. Capital Medical University
    Beijing, China
    Recruiting
    • Dong Yan · Contact
  • Peking University Cancer Hospital
    Beijing, China
    Recruiting
  • The first affiliated hospital of bengbu medical college
    Bengbu, China
    Recruiting
    • Jun Qian · Contact
    • Jun Qian · Principal investigator
    • Huan Zhou · Principal investigator
  • The First People's Hospital of Changzhou
    Changzhou, China
    Recruiting
    • Wenwei Hu · Contact
  • Chongqing University Cancer Hospital
    Chongqing, China
    Recruiting
    • Weiqi Nian · Contact
  • The Sixth Affiliated Hospital, Sun Yat-sen University
    Guangzhou, China
    Recruiting
    • Yanhong Deng · Contact
  • Zhongshan Hospital
    Shanghai, China
    Recruiting
    • Tianshu Liu · Contact
  • The First Affiliated Hospital of Soochow University
    Suzhou, China
    Recruiting
    • Weichang Chen · Contact
  • Henan Cancer Hospital
    Zhengzhou, China
    Not yet recruiting
    • Jufeng Wang · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2017 (actual). Primary completion is estimated for Dec 2021, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2020
First posted
Dec 30, 2020
StartActual
Apr 11, 2017
Primary completionEst.
Dec 31, 2021
CompletionEst.
Jun 30, 2022
Last update
Dec 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04689100
Responsible party
Sponsor
First posted
Dec 30, 2020
Start date
Apr 11, 2017
Primary completion
Dec 31, 2021 (estimated)
Completion
Jun 30, 2022 (estimated)
Last update
Dec 30, 2020

Study contacts

Xiugao Yang
Contact
yangxiugao@mail.ecspc.com
8021-60677906
Rong Hu
Contact
hurong@mail.ecspc.com
8021-60673935
Xiugao Yang
study chair · Department of Medicine, CSPC Clinical Development Division

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Becotatug

Start the discussion